Intravenous miR-144 reduces left ventricular remodeling after myocardial infarction
Jing Li1, Sean XiaoXiao Cai2, Quan He3
1Division of Cardiology, Labatt Family Heart Center, Hospital for Sick Children, Toronto, ON, Canada.
Abstract:
MicroRNA-144 is a cytoprotective miRNA. Our previous study showed that miR-144 provides potent acute cardioprotection in an ischemia/reperfusion injury model. This study was performed to further assess whether miR-144 improves post-MI remodeling in a non-reperfused myocardial infarction (MI) model. C57BL/6 mice were subjected to MI by permanent left anterior descending artery (LAD) ligation. miR-144 was delivered by intravenous injections of 8 mg/kg, 16 mg/kg, or 32 mg/kg at day 0, day 1, day 3, and then a similar dose given once every 3 days, until day 28 after MI. Cardiac function was evaluated using echocardiography. At the end of the study, heart function was also evaluated using a pressure volume catheter. The percentage of the length of the infarct scar on the left ventricle (LV) circumferential length was calculated for heart each section. The miR-144 KO mice showed a worse heart failure phenotype with ventricular dilation and impaired contractility after LAD ligation. Ischemia decreased miR-144 levels, and the miR-144 level was restored to baseline by administration of intravenous miR-144. Cy3-labeled miR-144 was localized to the infarct and border zone, and was taken up by cardiomyocytes and macrophages. In miR-144-treated groups, at 28 days MI size was significantly reduced, and cardiac function was improved [LV fractional shortening, end-systolic volume (µL), end-diastolic volume (µL), ejection fraction (%), dP/dt max (mmHg/s), dP/dt min (mmHg/s), Tau (ms)], compared with controls (p < 0.01). This beneficial effect was associated with reduced border zone fibrosis, inflammation and apoptosis, these effects were associated with significant changes in autophagy signaling. Intravenous miR-144 has potent effects on post-MI remodeling. These findings suggest that miR-144 has potential as a therapeutic agent after MI.
Insights
MicroRNA-144 therapy significantly improved heart function and reduced scar size after myocardial infarction (MI) in mice. This cytoprotective microRNA (miRNA) shows potential for treating heart damage by reducing fibrosis, inflammation, and apoptosis.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Regenerative Medicine
Background:
- MicroRNA-144 (miR-144) is a known cytoprotective microRNA.
- Previous research demonstrated miR-144's acute cardioprotective effects in ischemia/reperfusion injury models.
- The therapeutic potential of miR-144 in improving post-myocardial infarction (MI) cardiac remodeling remained to be fully elucidated.
Purpose of the Study:
- To investigate the efficacy of miR-144 in improving cardiac remodeling in a non-reperfused myocardial infarction (MI) mouse model.
- To assess the impact of miR-144 administration on cardiac function, infarct size, and associated pathological changes post-MI.
Main Methods:
- Myocardial infarction was induced in C57BL/6 mice via permanent left anterior descending artery (LAD) ligation.
- miR-144 was administered intravenously at varying doses (8-32 mg/kg) starting from day 0 post-MI, with repeated doses every 3 days until day 28.
- Cardiac function was assessed using echocardiography and pressure-volume catheterization; infarct size, fibrosis, inflammation, and apoptosis were quantified.
Main Results:
- Mice lacking miR-144 (miR-144 KO) exhibited exacerbated heart failure phenotypes, including ventricular dilation and impaired contractility.
- Intravenous miR-144 administration significantly reduced infarct size and improved cardiac function, including LV fractional shortening, ejection fraction, and contractility indices (dP/dt max/min).
- Beneficial effects were linked to reduced border zone fibrosis, inflammation, apoptosis, and modulated autophagy signaling, with miR-144 localized to cardiomyocytes and macrophages in the infarct area.
Conclusions:
- Intravenous delivery of miR-144 demonstrates potent therapeutic effects on post-myocardial infarction remodeling.
- miR-144 administration improves cardiac function and reduces adverse pathological changes following MI.
- These findings highlight miR-144 as a promising therapeutic agent for treating myocardial infarction and its sequelae.
More Related Videos
Related Concept Videos
Nucleosome Remodeling
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Bone Remodeling
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Osteoclasts in Bone Remodeling
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Adaptations that Reduce Water Loss


